Q2 2026 13F · SEC CIK 1773195

Affinity Asset Advisors, LLC

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $2.0B
Reported positions: 101
Top holdings a year, 3 yrs: +38.8%
Assets under management: $2.5B

Affinity Asset Advisors, LLC is a hedge fund that reported 101 positions worth $2.0B in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Roivant Sciences Ltd (ROIV, 6.6%), Apogee Therapeutics Inc (APGE, 6.5%), Spyre Therapeutics (SYRE, 5.6%). A portfolio copying its top holdings returned 38.8% a year over the last 3 years, against 22.3% for the S&P 500.

Affinity Asset Advisors, LLC holdings largest 50 of 101 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Affinity Asset Advisors, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
ROIVRoivant Sciences Ltd	6.6%	4.6%	3,750,000	+33.9%	$132.7M
APGEApogee Therapeutics Inc	6.5%	6.5%	987,000	-23.2%	$131.0M
SYRESpyre Therapeutics	5.6%	3.9%	1,279,134	+0.0%	$113.6M
XENEXenon Pharmaceuticals Inc	4.8%	5.8%	1,595,000	-4.8%	$96.3M
ERASErasca, Inc.	4.8%	5.2%	5,250,000	-1.9%	$96.2M
INSMInsmed Inc	3.4%	4.7%	650,000	+35.4%	$69.3M
PRAXPraxis Precision Medicines I	3.1%	3.3%	185,000	+8.8%	$61.9M
ALKSAlkermes PLC	2.9%	2.8%	1,125,000	-16.7%	$58.9M
ORKAOruka Therapeutics Inc	2.8%	1.5%	590,000	+18.1%	$56.2M
ANABAnaptysbio Inc	2.8%	3.1%	826,109	-12.1%	$55.8M
AVTXAvalo Therapeutics Inc	2.7%	1.2%	2,900,000	+116.3%	$53.6M
CYTKCytokinetics	2.3%	2.8%	550,000	-21.5%	$46.9M
RVMDRevolution Medicines Inc	2.3%	0.6%	250,000	+150.0%	$46.8M
ABVXAbivax SA	2.2%	2.7%	330,000	-18.5%	$44.0M
TRAXFirst Tracks Biotherapeutics	2.0%	—	2,032,012	—	$40.9M
DNTHDianthus Therapeutics Inc	1.9%	1.8%	400,000	+14.3%	$39.0M
STROSutro Biopharma Inc	1.9%	1.6%	1,172,487	+9.6%	$38.9M
NUVLNuvalent Inc	1.7%	1.8%	275,000	-8.3%	$34.0M
TRVITrevi Therapeutics Inc	1.7%	1.4%	1,800,172	-10.0%	$33.6M
OVIDOvid Therapeutics Inc	1.4%	1.4%	10,144,562	-4.6%	$27.3M
LXEOLexeo Therapeutics Inc	1.3%	1.7%	5,807,611	+15.0%	$27.0M
CLDXCelldex Therapeutics Inc New	1.3%	0.9%	700,000	+40.0%	$26.0M
BLTEBelite Bio Inc	1.3%	0.6%	165,000	+153.8%	$25.4M
ELVNEnliven Therapeutics Inc	1.3%	1.4%	500,000	-14.8%	$25.4M
FBRXForte Biosciences Inc	1.2%	1.6%	1,145,391	+13.2%	$24.3M
NRIXNurix Therapeutics Inc	1.2%	0.9%	967,620	+0.0%	$23.5M
ANROAlto Neuroscience Inc	1.1%	0.7%	850,000	+70.0%	$22.4M
MDGLMadrigal Pharmaceuticals Inc	1.1%	1.7%	40,000	-27.3%	$21.5M
PTGXProtagonist Therapeutics Inc	1.0%	1.1%	172,125	+0.0%	$21.1M
MLYSMineralys Therapeutics Inc	1.0%	1.2%	750,000	+0.0%	$20.2M
RLAYRelay Therapeutics Inc	1.0%	—	1,050,000	—	$19.6M
SGMTSagimet Biosciences Inc	1.0%	—	2,497,864	—	$19.3M
008064206Jade Biosciences Inc	0.9%	0.5%	840,350	+31.3%	$18.7M
COGTCogent Biosciences Inc	0.9%	1.7%	450,000	-40.0%	$17.4M
TVTXTravere Therapeutics Inc	0.8%	0.5%	300,000	+0.0%	$17.0M
CGEMCullinan Therapeutics Inc	0.8%	0.7%	875,760	+12.1%	$15.9M
SVRASavara Inc	0.8%	0.8%	2,512,153	+0.0%	$15.5M
IDYAIdeaya Biosciences Inc	0.7%	—	400,000	—	$14.9M
CATXPerspective Therapeutics Inc	0.7%	0.8%	4,214,582	+33.2%	$14.4M
ODTXOdyssey Therapeutics, Inc.	0.7%	—	766,346	—	$14.3M
HLXCHelix Acquisition Corp III	0.7%	0.8%	1,250,000	+0.0%	$13.3M
EQEquillium Inc	0.7%	—	4,100,000	—	$13.1M
ESTAEstablishment Labs Hldgs Inc	0.6%	—	148,013	—	$12.7M
CLYMClimb Bio Inc	0.6%	—	972,000	—	$12.7M
TEVATeva Pharmaceutical Inds Ltd	0.6%	2.5%	374,000	-73.3%	$12.7M
MANEVeradermics Inc	0.6%	—	100,000	—	$12.3M
ARWRArrowhead Pharmaceuticals in	0.6%	0.7%	150,000	-25.0%	$12.2M
TSHATaysha Gene Therapies Inc	0.6%	—	1,750,000	—	$11.9M
GLTODamora Therapeutics Inc	0.5%	0.7%	425,000	-5.6%	$11.1M
EPRXEupraxia Pharmaceuticals Inc	0.5%	0.7%	1,650,000	+3.8%	$10.9M

What Affinity Asset Advisors, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +16.1% /yr; S&P 500 +11.7%
3 years: +38.8% /yr; S&P 500 +22.3%
5 years: +11.7% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$2.0B	101
Q1 2026	$1.7B	92
Q4 2025	$1.4B	82
Q3 2025	$1.0B	82
Q2 2025	$650.9M	74
Q1 2025	$605.9M	78
Q4 2024	$591.7M	71
Q3 2024	$602.9M	73
Q2 2024	$578.4M	81
Q1 2024	$573.9M	73
Q4 2023	$474.0M	70
Q3 2023	$289.7M	68

Questions about Affinity Asset Advisors, LLC's portfolio

What stocks does Affinity Asset Advisors, LLC own?

Affinity Asset Advisors, LLC's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 101 positions worth $2.0B. The largest are Roivant Sciences Ltd (ROIV) at 6.6%, Apogee Therapeutics Inc (APGE) at 6.5%, Spyre Therapeutics (SYRE) at 5.6%, Xenon Pharmaceuticals Inc (XENE) at 4.8% and Erasca, Inc. (ERAS) at 4.8%.

What did Affinity Asset Advisors, LLC buy last quarter?

In Q2 2026, Affinity Asset Advisors, LLC added Belite Bio Inc (BLTE) (+153.8% shares), Revolution Medicines Inc (RVMD) (+150.0% shares) and Avalo Therapeutics Inc (AVTX) (+116.3% shares), compared with its Q1 2026 filing.

What did Affinity Asset Advisors, LLC sell last quarter?

In Q2 2026, Affinity Asset Advisors, LLC cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Arcellx Inc (ACLX), cut from its top 50 Terns Pharmaceuticals Inc (TERN), cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Zura Bio Ltd (ZURA), Teva Pharmaceutical Inds Ltd (TEVA) (-73.3% shares), Cogent Biosciences Inc (COGT) (-40.0% shares) and Madrigal Pharmaceuticals Inc (MDGL) (-27.3% shares), compared with its Q1 2026 filing.

How has Affinity Asset Advisors, LLC's portfolio performed?

A portfolio copying Affinity Asset Advisors, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +38.8% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +16.1% against +11.7%. Over 5 years: +11.7% a year against +10.6%.

When is Affinity Asset Advisors, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Affinity Asset Advisors, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Affinity Asset Advisors, LLC manage?

Affinity Asset Advisors, LLC reported $2.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $2.0B.